APOE and acute coronary syndrome: P2Y12 receptor represents a further very promising molecule for the treatment of the disease as its inhibitor Ticagrelor reduces cardiovascular events in patients with acute coronary syndrome and decreases inflammatory endothelial activation and vascular dysfunction in ApoE-/- mice (144, 145).